Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
Year: 2013
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: The University of Texas MD Anderson Cancer Center, The Catholic University of Korea Seoul St. Mary's Hospital, Emory University, Winship Cancer Institute, University Medical Center Hamburg-Eppendorf, Universitätsklinikum Aachen, RWTH Aachen University, Helsinki University Hospital, University of Bologna, Royal Brisbane and Women's Hospital, Pfizer (United States), Pfizer (France), University of Milano-Bicocca
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: bosutinib, tyrosine kinase inhibitors, Philadelphia chromosome-positive leukemia, chronic myeloid leukemia, imatinib resistance, imatinib intolerance, diarrhea, myelosuppression, alanine aminotransferase elevation, drug toxicity management, dose reduction, dose interruption, drug rechallenge
Open Access status: green
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W2059705970
